TITLE

A Review of the Effects of Disopyramide Phosphate on Left Ventricular Function and the Peripheral Circulation

AUTHOR(S)
Di Bianco, Robert; Gottdiener, John S.; Singh, Steven N.; Fletcher, Ross D.
PUB. DATE
February 1987
SOURCE
Angiology;Feb1987 Part 2, Vol. 38, p174
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In the absence of preexistent myocardial dysfunction, the risk of producing cardiac decompensation in patients being treated with any of the conventional antiarrhythmic agents is low. The availability of disopyramide for clinical use in 1977 produced optimism for an effective antiarrhythmic agent that was free of the well-known immediate and late toxicities of quinidine and procainamide. Unfortunately, shortly after its clinical introduction, reports appeared that raised concern about the negative inotropic actions of disopyramide and the possible role of this drug in precipitating heart failure. In clinical use, the frequency of adverse effects on ventricular function appeared to be out of proportion to disopyramide's greater negative inotropic activity and the contrasting (augmenting) effect on the peripheral vascular resistance compared to that of either quinidine or procainamide, suggesting that the other factors contributed to these observations. Review of the reported literature reveals that certain factors encourage such adverse reactions. These primarily include the routine use of oral and especially intravenous loading dosages of disopyramide in an effort to attain rapid onset of action, the failure to adequately reduce dosages of disopyramide in the setting of compromised renal function, and, most Importantly, the use of standard (and even loading) dosages in patients with active heart failure, compromised left ventricular function, or a history of heart failure. The avoidance of loading dosages of disopyramide, adequate reductions of maintenance dosages in the setting of renal insufficiency, gradual dose titration for additional drug action, and omission of patients with decompensated heart failure or significant left ventricular dysfunction should significantly enhance safety in the use of disopyramide.
ACCESSION #
16479031

 

Related Articles

  • The Pharmacokinetic and Pharmacodynamic Effects of Varying the Free Fraction of Disopyramide. Shaw, Leslie M.; Doherty, John U.; Waxman, Harvey L.; Josephson, Mark E. // Angiology;Feb1987 Part 2, Vol. 38, p192 

    We have evaluated the influence of several factors on the binding of disopyramide to protein in human serum using a new ultrafiltration system and the enzyme multiplied immunoassay technique (EMIT) for disopyramide immuno-assay. From these studies and those of other investigators, we conclude...

  • The Clinical Scope of Disopyramide Seven Years After Introduction -- An Overview. Willis III, Park W. // Angiology;Feb1987 Part 2, Vol. 38, p165 

    Disopyramide phosphate, seven years after its introduction, has proved to be a useful and effective Type IA oral agent for treatment of ventricular arrhythmias. The experience of these seven years has amplified and more sharply defined the initial efficiency and safety issues related to the use...

  • Pharmacologic Evaluation of Standard and Controlled-Release Disopyramide. Siddoway, Lyle A.; Barbey, J. Toby; Roden, Dan M.; Woosley, Raymond L. // Angiology;Feb1987 Part 2, Vol. 38, p184 

    Controlled-release disopyramide offers many potential advantages over the standard formulation for improved patient compliance, possible reduction of concentration-related adverse effects, and predictability of pharmacologic effect. The pharmacology of disopyramide, potential advantages and...

  • Long-Term Use of Controlled-Release Disopyramide in Patients with Severe Ventricular Arrhythmias. Paulk Jr., E. Alan // Angiology;Feb1987 Part 2, Vol. 38, p198 

    Controlled-release (CR) disopyramide phosphate has been available for the past four years for the management of patients with ventricular arrhythmias. The advantages of this preparation over the earlier form have for most patients been striking Improved patient compliance as regards dosing, ease...

  • Transfer from Immediate-Release Disopyramide to Controlled-Release Disopyramide. DiPersio, David M.; Chow, Moses S. S. // Angiology;Feb1987 Part 2, Vol. 38, p188 

    Simulation of serum disopyramide concentrations during transfer from steady-state immediate-release (IR) disopyramide to a sustained-release disopyramide preparation was performed based on pharmacokinetic parameters obtained from fit disopyramide and serum concentrations measured following an...

  • Enantioselective binding of disopyramide to α1-acid glycoprotein and its variants. Kishino, S.; Itoh, S.; Nakagawa, T.; Miyazaki, K. // European Journal of Clinical Pharmacology;Oct2001, Vol. 57 Issue 8, p583 

    Objective: α1-Acid glycoprotein (AAG) has three main genetic variants, F1, S, and A variants. There are few reports on the correlation between AAG variants and binding activity of drug enantiomers. We studied the differences between the binding characteristics of enantiomers of disopyramide...

  • Rythmodan Retard.  // Royal Society of Medicine: Medicines;2002, p483 

    The article presents information on rhythmodan retard, a proprietary, prescription-only preparation of the anti-arrhythmic disopyramide. It is available as modified-release tablets.

  • Stability-Indicating Methods for the Determination of Disopyramide Phosphate. Salem, Maissay Y.; Ramadan, Nesrin K.; Moustafa, Azza A.; El-Bardicy, Mohamed G. // Journal of AOAC International;Jul/Aug2006, Vol. 89 Issue 4, p976 

    The article reports on the methods used for the determination intact disopyramide phosphate in the presence of its degradation product. In the first and second, third-derivative spectrophotometric method, the peak amplitude was measured while for the derivative ratio spectrophotometric method....

  • Isomide CR.  // Royal Society of Medicine: Medicines;2002, p310 

    The article presents information on isomide CR, a proprietary, prescription-only preparation of the anti-arrhythmic disopyramide (as disopyramide phosphate), and is available as capsules.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics